Predictors for Retreatement of OAB After DC Mirabegron

National Taiwan University

Status: Completed

Conditions: Recurrence of Overactive Bladder Syndrome

Treatments: Drug: Mirabegron 25mg

Study type: Observational

Funder types: Other

Identifiers

NCT04550702

202006091RIND

Details and patient eligibility

About

Recurrence of female overactive bladder syndrome (OAB) is not uncommon. It is important to decrease the recurrence of female OAB. However, factors predicting recurrence of female OAB, especially for those women who need retreatment is undetermined. Thus, the aim of this study was to elucidate factors predicting retreatment of female OAB.

Full description

The medical records, including pad testing, urodynamic studies, lower urinary tract symptoms related questionnaires and bladder diaries of all consecutive women with OAB, who visited urogynecologic clinics in a tertiary referral center, were reviewed. Persistence interval was defined from the date of prescription of mirabegron to the date of discontinuation of mirabegron treatment. Statistical analysis was performed with Kaplan-Meier estimator. Multivariable Cox proportional-hazard model with all variables with p < 0.25 in the univariate analysis was performed to predict OAB retreatment probability.

Enrollment: 120 patients

Sex: Female

Ages: 20 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Women with overactive bladder syndrome
• Women complete urodynamic study and bladder diary

Exclusion criteria

• Pregnant women
• Incomplete data
• Loss of follow-up
• Acute or chronic urinary tract infection

Trial design

120 participants in 1 patient group

Women received Mirabegron

Description:

Women with overactive bladder syndrome received Mirabegron

Treatment:

Drug: Mirabegron 25mg